STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)
|
|
|
|
1 Months Ended |
8 Months Ended |
12 Months Ended |
May 08, 2025 |
Jul. 11, 2024 |
Jul. 08, 2024 |
Jun. 25, 2025 |
Aug. 31, 2024 |
Jun. 30, 2026 |
Oct. 31, 2025 |
Oct. 31, 2024 |
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Option vested |
|
|
|
|
|
103,333
|
105,000
|
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
792,500
|
180,000
|
185,000
|
| Fair value of the shares as of the date of grant |
|
|
|
|
|
$ 1,986,000
|
$ 473,000
|
$ 331,000
|
| Stock-based compensation expense |
|
|
|
|
|
4,930,000
|
4,693,000
|
3,853,000
|
| Unamortized compensation costs |
|
|
|
|
|
$ 3,575,000
|
|
|
| Purchased of warrants |
55,000
|
|
|
|
|
|
|
|
| Exercisable for a period |
5 years
|
|
|
|
|
|
|
|
| Exercise price |
$ 2.86
|
|
|
|
|
|
|
|
| Number of units sold |
|
|
|
|
|
8.2
|
|
|
| Aggregate purchase price |
|
|
|
|
|
$ 2,050,000
|
|
|
| Shares description |
|
|
|
|
|
Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 512,500 shares of common stock and 512,500 warrants to purchase shares of common stock.
|
|
|
| BioLumina, LLC [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Warrants description |
|
|
|
Company received notice from a holder of warrants to exercise 21,277 warrants to purchase 21,277 shares of common stock of the Company for a total exercise price of $50,000 ($2.35 per share). The proceeds were received, and the shares were issued on July 30, 2025.
|
|
|
|
|
| Two Consultants [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
$ 1,645,000
|
|
|
|
|
|
|
| Third party [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
|
|
|
$ 185,000
|
|
|
|
| Options Vesting [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
|
|
|
|
$ 3,596,000
|
1,523,000
|
953,000
|
| Options Outstanding [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
51,000
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
|
|
|
|
$ 215,000
|
2,937,000
|
2,450,000
|
| Warrant to purchase |
|
350,000
|
83,333
|
|
100,000
|
|
|
|
| Exercise price |
|
$ 2.35
|
$ 2.00
|
|
|
$ 5.00
|
|
|
| Term |
|
10 years
|
|
|
3 years
|
|
|
|
| Risk free interest rate |
|
4.20%
|
|
|
3.96%
|
|
|
|
| Warrants exercisable period |
|
10 years
|
|
|
|
|
|
|
| Expected stock volatility |
|
159.00%
|
|
|
147.00%
|
|
|
|
| Expected dividend rate |
|
0.00%
|
|
|
0.00%
|
|
|
|
| Fair value of warrants granted |
|
$ 1,645,000
|
|
|
$ 185,000
|
|
|
|
| Unamortized compensation costs |
|
|
|
|
|
$ 231,000
|
$ 1,270,000
|
$ 3,005,000
|
| Equity Option [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
|
|
|
|
$ 231,000
|
|
|
| Dr. Leider [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Option vested |
|
|
|
|
|
|
95,000
|
|
| Dr. Howard Golub [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Option vested |
|
|
|
|
|
|
250,000
|
|
| Employee [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Option vested |
|
|
|
|
|
|
20,000
|
|
| Director [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Vesting period |
|
|
|
|
|
|
options vest annually over 3 years, expire five years from the date of grant
|
The options vest over various periods ranging from 6 months to 3 years, expire five to ten years from the date of grant and had an aggregate fair value of $1,438,000 at the date of grant.
|
| Option grant date fair value |
|
|
|
|
|
|
$ 39,000
|
$ 1,438,000
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
|
11,341
|
|
| Dr. Everts [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Vesting period |
|
|
|
|
|
|
options vest over a five-year period.
|
|
| Option grant date fair value |
|
|
|
|
|
|
$ 177,000
|
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
|
65,000
|
|
| Dr. Everts [Member] | Equity Option [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Expected dividend rate |
|
|
|
|
|
|
|
|
| Employees, officers and directors [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Grant of unvested restricted common stock |
165,000
|
|
|
|
|
|
|
|
| Fair value of the shares as of the date of grant |
$ 472,000
|
|
|
|
|
|
|
|
| Stock-based compensation expense |
|
|
|
|
|
$ 3,456,000
|
$ 1,289,000
|
$ 776,000
|
| Employees, officers and directors [Member] | Equity Option [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Term |
|
|
|
|
|
|
5 years
|
6 years
|
| Expected dividend rate |
|
|
|
|
|
|
|
|
| Employees [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures |
|
|
|
|
|
7,790
|
|
|
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value |
|
|
|
|
|
$ 20,000
|
|
|
| Number of shares issued |
|
|
|
|
|
|
85,877
|
|
| Consultants [Member] | Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Grant of unvested restricted common stock description |
In connection with the Consulting Agreement discussed in Note 12, during May 2025, the Company granted the Consultant warrants to purchase 500,000 shares of its common stock (the “Warrants”). The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%.
|
|
|
|
|
|
|
|
| 4 Tranches [Member] | Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
| Warrant to purchase |
|
|
|
|
|
400,000
|
|
|
| Unamortized compensation costs |
|
|
|
|
|
$ 1,141,000
|
|
|